Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Summary Background Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet HIV 2017-05, Vol.4 (5), p.e195-e204
Hauptverfasser:	Orkin, Chloe, MD, DeJesus, Edwin, MD, Ramgopal, Moti, MD, Crofoot, Gordon, MD, Ruane, Peter, MD, LaMarca, Anthony, MD, Mills, Anthony, MD, Vandercam, Bernard, MD, de Wet, Joseph, MD, Rockstroh, Jürgen, MD, Lazzarin, Adriano, MD, Rijnders, Bart, MD, Podzamczer, Daniel, MD, Thalme, Anders, MD, Stoeckle, Marcel, MD, Porter, Danielle, PhD, Liu, Hui C, PhD, Cheng, Andrew, MD, Quirk, Erin, MD, SenGupta, Devi, MD, Cao, Huyen, Dr
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Adenine - therapeutic use Adult AIDS/HIV Anti-HIV Agents - therapeutic use Drug Therapy, Combination Emtricitabine - therapeutic use Female HIV Infections - drug therapy HIV Infections - virology HIV-1 - drug effects HIV-1 - physiology Humans Infectious Disease Male Middle Aged Rilpivirine - therapeutic use Tenofovir - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!